FANCD2 depletion sensitizes cancer cells repopulation ability in vitro

Cancer Letters

Volumn 256, Issue 2, 2007, Pages 186-195

  Lyakhovich, Alex ^a,b   Surralles, Jordi ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cancer therapy; DNA repair; FA BRCA pathway; Fanconi anemia; siRNA

Indexed keywords

FANCONI ANEMIA GROUP D2 PROTEIN; MITOMYCIN C; SMALL INTERFERING RNA;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL POPULATION; CORRELATION ANALYSIS; DRUG SENSITIVITY; DRUG SENSITIZATION; GAMMA RADIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CANCER; PRIORITY JOURNAL; RNA INTERFERENCE;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MITOMYCIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 34548663550     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.06.006     Document Type: Article

References (58)

1. Gibson M.K., and Forastiere A.A. Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol. 7 (2006) 565-574
2. Bernier J., Hall E.J., and Giaccia A. Radiation oncology: a century of achievements. Nat. Rev. Cancer 9 (2004) 737-747
3. Jeremic B. Radiation therapy. Hematol. Oncol. Clin. North Am. (2004) 1-12
4. Parra-Delgado H., Garcia-Pillado F., Sordo M., Ramirez-Apan T., Martinez Vazquez M., and Ostrosky-Wegman P. Evaluation of the cytotoxicity, cytostaticity and genotoxicity of argentatins A and B from Parthenium argentatum (Gray). Life Sci. 77 (2005) 2855-2865
5. Yu R.X., and Holmgren E. Endpoints for agents that slow tumor growth. Contemp. Clin. Trials 7 (2006) 1-7
6. Lucas R., Kresse M., Latta M., and Wendel A. Tumor necrosis factor: how to make a killer molecule tumor-specific?. Curr. Cancer Drug Targets 6 (2005) 381-392
7. Kurzeder C., Sauer G., and Deissler H. Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy. Curr. Cancer Drug Targets 3 (2004) 207-227
8. Roninson I.B., Broude E.V., and Chang B.D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumour cells. Drug Resist. Updat. 5 (2001) 303-313
9. Moureau-Zabotto L., Ricci S., Lefranc J.P., Coulet F., Genestie C., Antoine M., Uzan S., Lotz J.P., Touboul E., and Lacave R. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br. J. Cancer 4 (2006) 473-480
10. Milas L., Raju U., Liao Z., and Ajani J. Targeting molecular determinants of tumor chemo-radioresistance. Semin. Oncol. 32 (2005) 78-81
11. Allan J.M., and Travis L.B. Mechanisms of therapy-related carcinogenesis. Nat. Rev. Cancer 12 (2004) 943-955
12. Travis L.B. Therapy-associated solid tumors. Acta Oncol. 4 (2004) 323-333
13. Griesinger F., Metz M., Trumper L., Schulz T., and Haase D. Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB. Lung Cancer 44 (2006) 261-265
14. Alkureishi L.W., de Bree R., and Ross G.L. RADPLAT: an alternative to surgery?. Oncologist 5 (2006) 469-480
15. Friedmann A.M., Hudson M.M., Weinstein H.J., Donaldson S.S., Kun L., Tarbell N.J., and Link M.P. Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J. Clin. Oncol. 20 (2002) 3088-3094
16. Dash A.K., and Cudworth G.C. Therapeutic applications of implantable drug delivery systems. J. Pharmacol. Toxicol. Methods 40 (1998) 1-12
17. Ikuta K., Takemura K., Kihara M., Naito S., Lee E., Shimizu E., and Yamauchi A. Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells. Oncol. Rep. 13 (2005) 1229-1234
18. Vasir J.K., and Labhasetwar V. Targeted drug delivery in cancer therapy. Technol. Cancer Res. Treat. 4 (2005) 363-374
19. Kennedy R.D., and D'Andrea A.D. DNA repair pathways in clinical practice: lessons from paediatric cancer susceptibility syndromes. J. Clin. Oncol. 24 (2006) 3799-3808
20. Thompson L. Unraveling the Fanconi anemia-DNA repair connection. Nat. Genet. 37 (2005) 921-922
21. Xia B., Dorsman J.C., Ameziane N., de Vries Y., Rooimans M.A., Sheng Q., Pals G., Errami A., Gluckman E., Llera J., Wang W., Livingston D.M., Joenje H., and de Winter J.P. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat. Genet. 39 (2007) 159-161
22. Reid S., Schindler D., Hanenberg H., Barker K., Hanks S., Kalb R., Neveling K., Kelly P., Seal S., Freund M., Wurm M., Batish S.D., Lach F.P., Yetgin S., Neitzel H., Ariffin H., Tischkowitz M., Mathew K.M., Auerbach A.D., and Rahman N. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet. 39 (2007) 162-164
23. Smogorzewska A., Matsuoka S., Vinciguerra P., McDonald III E.R., Hurov K.E., Luo J., Ballif B.A., Gygi S.P., Hofmann K., D'Andrea A.D., and Elledge S.J. Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair. Cell 129 (2007) 289-301
24. Surrallés J., Jackson S.P., Jasin M., Kastan M.B., West S.C., and Joenje H. Molecular cross talk among chromosome fragility syndromes. Genes Dev. 18 (2004) 1359-1370
25. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn S.M., Timmers C., Hejna J., Grompe M., and D'Andrea A.D. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7 (2001) 249-262
26. Taniguchi T., Garcia-Higuera I., Andreassen P.R., Gregory R.C., Grompe M., and D'Andrea A.D. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 100 (2002) 2414-2420
27. Andreassen P.R., D'Andrea A.D., and Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev. 18 (2004) 1958-1963
28. Hussain S., Wilson J.B., Medhurst A.L., Hejna J., Witt E., Ananth S., Davies A., Masson A.Y., Moses R., West S.C., de Winter J.P., Ashworth A., Jones N.J., and Mathew C.G. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum. Mol. Genet. 13 (2004) 1241-1248
29. Hussain S., Wilson J.B., Blom E., Thompson L.H., Sung P., Gordon S.M., Kupfer G.M., Joenje H., Mathew C.G., and Jones N.J. Tetratricopeptide-motif-mediated interaction of FANCG with recombination proteins XRCC3 and BRCA2. DNA Repair (Amst.). 5 5 (2006) 629-640
30. Pichierri P., and Rosselli F. Fanconi anemia proteins and the s phase checkpoint. Cell Cycle 3 (2004) 698-700
31. Sobeck A., Stone S., Costanzo V., de Graaf B., Reuter T., de Winter J.P., Wallisch M., Akkari Y., Olson S., Wang W., Joenje H., Christian J.L., Lupardus P.J., Cimprich K.A., Gautier J., and Hoatlin M.E. Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks. Mol. Cell. Biol. 26 (2006) 425-437
32. Taniguchi T., Tischkowitz M., Ameziane N., Hodgson S.V., Mathew C.G., Joenje N., Mok N.C., and D'Andrea A.D. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 5 (2003) 568-574
33. D'Andrea A.D., and Grompe M. The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer 1 (2003) 23-34
34. Olopade O.I., and Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 5 (2003) 417-420
35. D'Andrea A.D. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2 (2003) 290-292
36. Lyakhovich A., and Surralles J. Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. Cancer Lett. 232 (2006) 99-106
37. Soulier J., Leblanc T., Larghero T., Dastot H., Shimamura A., Guardiola P., Esperou H., Ferry C., Jubert C., Feugeas J.P., Henri A., Toubert A., Socie G., Baruchel A., Sigaux F., D'Andrea A.D., and Gluckman E. Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood 105 (2006) 1329-1336
38. Chirnomas D., Taniguchi T., de la Vega M., Vaidya A.P., Vasserman M., Hartman A.R., Kennedy R., Foster R., Mahoney J., Seiden M.V., and D'Andrea A.D. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol. Cancer Ther. 4 (2006) 952-961
39. Pai S.I., Lin Y.Y., Macaes B., Meneshian A., Hung C.F., and Wu T.C. Prospects of RNA interference therapy for cancer. Gene Ther. 6 (2006) 464-477
40. Shekhar M.P., Lyakhovich A., Visscher D.W., Heng H., and Kondrat N. Rad6 overexpression induces multinucleation, centrosome amplification. abnormal mitosis, aneuploidy, and transformation. Cancer Res. 62 (2002) 2115-2124
41. Bogliolo M., Lyakhovich A., Callén C., Castellà M., Cappelli E., Ramírez M.J., Creus A., Marcos R., Kalb R., Neveling K., Schindler D., and Surralles J. Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. EMBO J. 26 (2007) 1340-1351
42. Zhang M., Zhang X., Bai C.X., Chen J., and Wei M.Q. Inhibition of epidermal growth factor receptor by RNA interference in A549 cells. Acta Pharmacol. Sin. 25 (2004) 61-67
43. Nijman S.M., Huang T.T., Dirac A.M., Brummelkamp T.R., Kerkhoven R.M., D'Andrea A.D., and Bernards R. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 3 (2005) 331-339
44. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr. Opin. Oncol. 1 (2005) 55-60
45. Avram D., Romijn E.P., Pap E.H., Heck A.J., and Wirtz W.K. Identification of proteins in activated human neutrophils susceptible to tyrosyl radical attack, A proteomic study using a tyrosylating fluorophore. Proteomics 4 (2005) 2397-2407
46. McCabe N., Turner N.C., Lord C.J., Kluzek K., Bialkowska A., Swift S., Giavara S., O'Connor M.J., Tut M.N., Zdzienicka M.Z., Smith G.C., and Ashworth A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to Poly(ADP-Ribose) polymerase inhibition. Cancer Res. 66 (2006) 8109-8115
47. Rossi A., Ciafre S., Balsamo M., Pierimarchi P., and Santoro M.G. Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res. 66 (2006) 7678-7685
48. Stege A., Priebsch A., Nieth C., and Lage H. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther. 11 (2004) 699-706
49. Gallmeier E., and Kern S.E. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models. Clin. Cancer Res. 13 (2007) 4-10
50. Wilda M., Fuchs U., Wossmann W., and Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 21 (2006) 5716-5724
51. Bartz S.R., Zhang Z., Burchard J., Imakura M., Martin M., Palmieri A., Needham R., Guo J., Gordon M., and Chung N. siRNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol. Cell. Biol. 26 (2006) 9377-9386
52. Navarro S., Meza N.W., Quintana-Bustamante O., Casado J.A., Jacome A., McAllister K., Puerto S., Surralles J., Segovia J.C., and Bueren J.A. Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1. Mol. Ther. 4 (2006) 525-535
53. Taniguchi T., and D'Andrea A.D. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107 (2006) 4223-4233
54. Cheung H.W., Chun A.C., Wang Q., Deng W., Hu L., Guan X.Y., Nicholls J.M., Ling M.T., Chuan W.Y., Tsao S.W., Jin D.Y., and Wang X. Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents. Cancer Res. 66 (2006) 4357-4367
55. Gallmeier E., Calhoun E.C., Rago C., Brody J.R., Cunningham S.C., Hucl T., Gorospe M., Kohli M., Lengauer C., and Kern S.E. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology 130 (2006) 2145-2154
56. Narayan G., Arias-Pulido H., Nandula S.V., Basso K., Sugirtharaj D.D., Vargas H., Mansukhani M., Villella J., Meyer L., Schneider A., Gissmann L., Durst M., Pothuri B., and Murty V.V. Promoter hypermethylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res. 64 (2004) 2994-2997
57. Tischkowitz M., Ameziane N., Waisfisz Q., De Winter J.P., Harris R., Taniguchi T., D'Andrea A., Hodgson S.V., Mathew C.G., and Joenje H. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. J. Haematol. 3 (2003) 469-471
58. Tischkowitz M.D., Morgan N.V., Grimwade D., Eddy C., Ball S., Vorechowsky I., Langabeer S., Stoger R., Hodgson S.V., and Mathew C.G. Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia 18 (2004) 420-425